Cr(III)/cm2-skin, otherwise Cr(III) was unable to produce allergic contact dermatitis in these highly sensitive volunteers. Two supplemental studies were also conducted to assess whether the surface area of the patch and the concentration of Cr(VI) in the patch (related to patch thickness) were likely to influence the results. The data from these studies were used to assess the risk of developing allergic contact dermatitis due to contact with Cr(VI) and Cr(III) in soil. The findings indicated that soil concentrations at least as high as 450 ppm Cr(VI) and 165 000 ppm Cr(Ill) should not pose an allergic contact dermatitis hazard for at least 99*99%/o of the people in the community who might be exposed.
determine the MET (mg allergenlcm2) for Cr(VI) and trivalent chromium (Cr(III)) by patch testing techniques. A patch test method that delivers a controlled amount of allergen per surface area of skin was used. A group of 54 Cr(VI) sensitised volunteers were patch tested with serial dilutions of Cr(VI) and Cr(III) to determine the cumulative response rate at several concentrations. The results indicate that the 10% MET for Cr(VI) based on the cumulative response was 0-089 pg Cr(VI)/cm2-skin. Only one of the 54 volunteers may have responded to 33,ug Cr(III)/cm2-skin, otherwise Cr(III) was unable to produce allergic contact dermatitis in these highly sensitive volunteers. Two supplemental studies were also conducted to assess whether the surface area of the patch and the concentration of Cr(VI) in the patch (related to patch thickness) were likely to influence the results. The data from these studies were used to assess the risk of developing allergic contact dermatitis due to contact with Cr(VI) and Cr(III) in soil. The findings indicated that soil concentrations at least as high as 450 ppm Cr(VI) and 165 000 ppm Cr(Ill) should not pose an allergic contact dermatitis hazard for at least 99*99%/o of the people in the community who might be exposed.
(Occup Environ Med 1994;51:371-380) Hexavalent chromium Cr(VI) is one of the most common dermal sensitisers in the occupational setting and accounts for about 5% of clinically reported cases of allergic contact dermatitis in the United States.' Cr(VI) related allergic contact dermatitis has been reported in chromium plating workers,23 lithographers,4 diesel repair shop workers,5 and leather workers.6 Additionally, Cr(VI) in household products such as bleaches and detergents, cosmetics, and shoe polish has been cited as a potential cause of allergic contact dermatitis.' I In many areas, there can be appreciable human exposure to chromite ore processing residue (COPR) and mine tailings when either is mixed with soil. 8 Cr(VI) induced allergic contact dermatitis is known as a type IV, delayed, or cell mediated allergic reaction. ' 29 The localised biological response of allergic contact dermatitis is similar to a "poison oak" hypersensitive reaction, and elicits the standard symptoms of erythema, oedema, and small vesicles.' 9 10 Type IV allergic dermatitis reactions are most often not life threatening and their effect is generally limited to the skin. Sensitisation is a threshold response where single or repeated exposure to low doses of an allergen may not produce an allergic response if the threshold dose is not reached.8 Epidermal contact with high concentrations of Cr(VI) can also produce irritant contact dermatitis, which is a heterogeneous symptom wherein a chemical induces a non-immunological dermatitis.""-'
A cutaneous irritant causes direct damage to the skin without prior sensitisation. ' 12 It has been known since 1925 that dermal contact with Cr(VI) can elicit allergic dermatoses.'4 Due to the strong sensitising potential of Cr(VI) and the desire to reduce the incidence of allergies in workers, several studies involving patch testing have been conducted to determine the "minimum elicitation threshold" (MET) of Cr(VI) in sensitised persons."52" In those studies, people known to be Cr(VI) sensitive were tested with patches containing serial dilutions of Cr(VI) (usually as potassium dichromate (K2Cr2O,)) in petroleum jelly, water, and/or acid-glycine.
Dose-response studies of dermal sensitisers conducted before 1988 were much less complex than those used today. For 26 Paustenbach et a127 examined the data from the same studies and suggested that the 10% MET should be about 50 ppm Cr(VI) in solution.
Certainly, the most important deficiency in these studies with respect to their usefulness in environmental risk assessment is that the data were not reported in terms of mass of allergen per unit area (for example, mg/cm2). As has been discussed elsewhere, by contrast with using patch tests to identify those chemicals to which a person is sensitised (a qualitative decision), in order to perform health risk assessments patch testing data must be presented in terms of mg of chemical per skin area. 24 Specifically, single patches were added to 1-5 ml of 0 1 M sodium hydroxide and heated to 85'C for one hour, followed by the addition of 300,ul 30% hydrogen peroxide and heat for another hour. Two millilitres of 0 1 M hydrochloric acid were added to the digestant after heating and the solution was cooled to room temperature. Another 2-2 ml 0-1 M hydrochloric acid was then added to the solution and the volume was adjusted to 25 ml with purified water. The patch digestants were then analysed for total Cr (as CrCl,) by EPA Method 6010, or Inductively Coupled Plasma (ICP). The EPA Method 6010 measures element emitted light by optical spectrometry at 267-7 nm. After the CrCl, is digested, the ICP column is calibrated with stock solutions of 2 ml (1: 1) HNO and 10 ml (1: 1) HCL and diluted to 100 ml with type II water. The digestant is directly injected into the column (about 2 ml) through the torch and a direct reading is taken from the instrument.
Representative patches of each Cr concentration were analysed in duplicate to evaluate interpatch variability. As part of the confirmation analyses, matrix spikes and matrix spike duplicates (MS/MSDs) were analysed by spiking selected patches with 10ul of KCrO, at a concentration 10 times that of the patch concentration to assess recovery. The KCrO, patches analysed by modified NIOSH 7600/IC-VAS were within 89-101% of the theoretical Cr(VI) concentrations. Also, the MS/MSDs averaged 121% and 111-5% for the 44pug Cr(VI)/cm2 and 0-018,ug Cr(VI)/cm2 patches with reported relative percentage differences (RPDs) of 2% for both. Therefore, the patch concentrations were within Contract Laboratory Procedure (CLP) criteria for acceptable variability (± 25%).
Additionally, the K2Cr2,7 patches analysed for total Cr using EPA Method 6010 were within 88-97% of the theoretical total Cr concentrations. The MS/MSDs measured for the 4-4,ug Cr(VI)/cm2 patch were both 106%.
We analysed the data by SYSTAT version 5-0 by the paired t test with a 95% confidence level and the data sets were not statistically different. Hence, the Cr(VI) concentrations measured were considered to be stable in the hexavalent form and in the appropriate amounts.
The concentrations of total Cr in the Cr(III) patches ranged from 89%-105% of the theoretical concentrations. The MS/MSDs measured for the 33 ug Cr(III)/cm2 concentration were 90% and 80% respectively. The 0 33,ug Cr(III)/cm2 MS/MSD concentrations were 110% and 113%, respectively, with reported RPDs of 3% for both. The Cr(III) patches were also analysed for Cr(VI) by the modified NIOSH 7600/IC-VAS method and none was found. In summary, these analyses were reproducible and within the CLP acceptable range. Blank patches were also analysed for Cr(VI) and Cr(III). No Cr was detected on either patches using reported limits of 0-00025 mg/cm2 for Cr(III) and 0-000015 mg/cm2 for Cr(VI). Representative patches were reanalysed about every three months, and, in every instance, the appropriate valency states and concentrations did not change (less than 5%) throughout the duration of the study (about one year).
STUDY DESIGN

Patch concentrations
The Cr(VI) patch concentrations used in this study were chosen based on our best estimates of a range that would provide a maximal (100%) response at the highest concentration and a minimal response (< 10%) at the lowest concentration. This is similar to the design of other patch testing studies.28 Based on the theoretical underpinnings of the doseresponse relation50 our review of the literature suggested that an approximate 250-fold range of Cr(VI) concentrations from 0-018 to 44 ,ug Cr(VI)/cm2 would yield useful results.
Similarly, for Cr(III), a 50-fold range of concentrations (0-66-33 ug Cr(III)/cm2) was chosen based on previously published data.5' Patch testing strategy The patch testing study was designed to occur in three rounds. In the first round, all subjects were tested with a diagnostic Cr(VI) patch (44 4ug Cr(VI)/cm2) to confirm that all volunteers in the study were allergic to Cr(VI).
Those who were confirmed as sensitised in round one were then tested in round two with the two lowest Cr(VI) concentrations and all four Cr(III) concentrations. If the subjects responded to both of the Cr(VI) patches or only to the higher concentration (0-088 pg Cr(VI)/cm2), a threshold was considered to have been identified and the subjects did not complete round three. If no response occurred at either of the two low Cr(VI) concentrations, then the subjects were tested in round three with the two higher Cr(VI)-concentrations. For each subject, the lowest Cr(VI) concentration at which a positive response occurred was considered to be the MET for that subject.
The rationale for testing with low Cr(VI) concentrations initially, followed by higher concentrations if necessary, was to minimise the incidence of "false positives" and "excited skin syndrome" that can occur when multiple patches are applied to the subject's skin in a single dosing. 52 Population size Before starting the study, an analysis was performed to estimate the total number of subjects required to achieve acceptable statistical power. Our goal was to identify a lower threshold at which no more than 10% of the Cr(VI) sensitive subjects would respond with 90% confidence. A figure of 10% was used since a number of dermatologists indicated that it would be very difficult to accurately identify through testing a 1%-5% value because 10% is probably very close to the threshold dose for all people (including the most sensitised). Estimating the number of subjects needed for the study required an assumption about the number of responders at a particular test concentration. Based on results of previous reports56 we concluded that about 50-80 subjects would be required to meet these criteria.
It was anticipated that a number of the subjects may have actually had irritant, atopic, or "excited skin syndrome" reactions, rather than a true allergic contact dermatitis response during previous testing and that about 80% of the initial subjects would, on round one testing, show a strong positive response to Cr(VI). Of these, it was estimated that at least 75% of sensitised persons would consent to participate in the proposed studies and complete the required testing rounds. The drop out rate for these subjects was not known, but was not expected to exceed 10%-20%. In summary, to have a study population of no less than 50 subjects, it was determined that we needed to find about 100 Cr(VI) sensitised volunteers.
PARTICIPATING PHYSICIANS AND STUDY POPULATION
Participating physicians Six practising dermatologists conducted the clinical aspects of the study (Dr Robert Adams, Dr Joseph Fowler, Dr James Marks, Dr Charles Morton, Dr James Nethercott, and Dr James Taylor). They also participated in the study design.
Study population More than 6000 patient files from various dermatologists (who specialised in patch testing) were examined before 100 possible volunteers were identified. Eventually, a group of 113 potential subjects were found by the participating physicians, of which 102 eventually took part in the study (11 subjects dropped out due to personal reasons). All were believed to be Cr(VI) sensitised based primarily on previous clinical patch tests performed by these physicians. As presented in table 2, this initial study population consisted of 78 men (76%) and 24 women (24%). All were over 18 years of age. Persons taking immunosuppressive or steroidal medications and pregnant women were excluded from the study. Subjects with eczema at the scheduled time of testing were not tested until the dermatitis subsided and it was requested that topical steroids not be used for two weeks before testing. All volunteers provided their doctors with written consent to participate in the study.
Patient questionnaire Before initial testing, each patient filled out a medical and occupational history questionnaire. Each questionnaire was screened by a qualified person to insure proper completion. The medical history discussed in the form included incidence, type, and duration of past present dermatitis and other known allergies including asthma and any other skin problems or sensitivities. The questionnaire also asked for history of jobs held and corresponding duration, as well as any known or potential exposure to Cr in the workplace. Use of over the counter medications and vitamins was also recorded. The purpose of collecting this information was to assess whether previous exposure to Cr compounds was a significant factor in individual METs. Information on allergic and atopic dermatitis was available for all of the 102 subjects. The data were analysed by a computer modelled data technique.58 A truncated log normal distribution was fitted to the data with maximum likelihood methods, which is a technique for choosing parameters of a selected distribution of the observed data such that the probability of response of the observed data is maximised. 59 The fit to the data was excellent as confirmed by thex2 goodness of fit test, which gave a p value of >0 05. The 10% cumulative response MET for Cr(VI) was 0-089 pg/cm2. The log normal distribution is conventionally used in the analysis of bioassay data and was used here.60 Because a reaction at the maximum tested concentration was a criterion for inclusion in the study, the distribution of response concentrations is truncated. Thus the truncated log normal distribution was fitted to the dataset with the highest truncation point being the highest Cr(VI) concentration tested (44 pig Cr(VI)/cm2).
IMPORTANCE OF PATCH CONCENTRATION
Recently, some dermatologists have concluded that the mass of allergen per unit area of skin is the correct measure of dermal dose, not the applied patch concentration of allergen.29 To assess the influence of the concentration in the patch test material v the dose applied in mass per unit area on the potential to elicit a response, two different sets of patches were prepared. The first set was prepared with the gel material normally used to manufacture the 0-88 ug Cr(VI)/cm2 patch. A second patch was constructed from the same gel but it was only 1/7 as thick (the thin patch). Hence, the thin patches contained 0-13 pg Cr(VI)/cm2, but were identical to the 0 88 pg Cr(VI)/cm2 patch with respect to mass of Cr(VI) per mass of patch (in this case, 175 ppm). These patches were then evaluated with nine volunteers previously shown to have a MET of 0-88 pg Cr(VI)/cm2. The results (table 6) indicate that six of the nine subjects showed a response deemed to be morphologically positive at 0-88 pg Cr(VI)/cm2 but none showed such a response at 0-13 pg Cr(VI)/cm2. Thus although both patches were identical on a mass of Cr(VI)/mass of patch basis (175 "ppm" Cr(VI)) the elicited response was different indicating that mass per unit arrea is a more appropriate measure of dose. Hence, as predicted by Upadhye and Maibach,29 the mass of allergen per unit area of skin, and not the mass of Cr(VI)/mass of patch (concentra- although it is still used in Europe. Many dermatologists in North America believe that use of 0-25% K2CrO, to identify sensitisation, as was done in this study, minimises or eliminates the incidence of irritant reactions.36 Therefore, it is likely that many of those volunteers who initially reacted to 0 5% K2Cr2O, exhibited an irritant (false positive) reaction in earlier testing and that the 0-25% K2Cr2O, patch used in this study failed to produce the irritant response. Alternatively, it is possible that some of the subjects who failed to respond in round one truly are Cr(VI) sensitive but have a threshold that is greater than 0-25% KCrO,. If this is true, then the results of our study could be considered "worst case" as only the hypersensitive volunteers were used to represent the sensitised population.
The results of this study suggest that the 10% MET for Cr(VI) induced allergic contact dermatitis is approximately 0-089 pugCr(VI)/cm2. No significant correlations between age, sex, or occupation were found at any of the tested concentrations.
Several estimates of the prevalence of Cr(VI) related allergic contact dermatitis in the general population have been published in the past three years. Hostynek and Maibach estimated that less than 1% of the general population is Cr(VI) sensitive based on their review of several years of clinical data. 7 Paustenbach et a18 estimated that about 07% of the general population is Cr(VI) sensitive. Finally, in a review of clinical data collected from several hundred human volunteers, Nethercott57 estimated that "a 06% prevalence is likely a reasonable reflection of the prevalence of Cr(VI) sensitivity in the general population, although false positive irritant responses to 05% K2Cr,07 in petroleum jelly may explain even some of these responses." In all three analyses, if one excludes those who have had more than 10 years of experience working with wet cement, the prevalence of Cr(VI) sensitisation in the general population is probably no greater than 0 1%. Therefore, if Cr(VI) sensitised subjects comprise less than 0-1% of the general population, an allergic contact dermatitis based soil clean up criterion that is protective of 10% of the Cr(VI) sensitised population will probably be protective of about 99 99% of the general population.
When attempting to use these data to identify safe concentrations of Cr(VI) in environmental media (soil, dust, etc), it is necessary to consider whether children are more or less prone to Cr(VI) sensitisation than adults. In general, most authorities believe that sensitivity to contact allergens increases with age, due primarily to increased exposure.626' Children under the age of three react less often and less intensely than older children, whereas children older than three react to contact allergens in a manner similar to adults. 
